NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2

Recruiting

Conditions: Paraganglioma
Neuroendocrine Neoplasms
Pheochromocytoma
Neuroendocrine Tumors

Interventions: Drug: Lu-177-DOTATATE
Drug: Ga-68-DOTATATE
Drug: F-18-FDG
Drug: Amino Acid solution

First Posted Date: 2017-07-02

Last Posted Date: 2025-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT03206060

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NCI UNC Project ESCC

Terminated

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2017-07-02

Last Posted Date: 2020-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 648

Registration Number: NCT03206125

Locations: 🇲🇼
Kazumu Central Hospital (KCH), Lilongwe, Malawi
🇲🇼
St Gabriel's Hospital, Namitete, Malawi

Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

Phase 2

Completed

Conditions: Gallbladder Carcinoma
Metastatic Cholangiocarcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Unresectable Cholangiocarcinoma
Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

Interventions: Drug: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cobimetinib
Procedure: Magnetic Resonance Imaging

First Posted Date: 2017-06-28

Last Posted Date: 2024-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT03201458

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 38 locations

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3

Active, not recruiting

Conditions: Unresectable HER2-Positive Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Metastatic Breast Adenocarcinoma
Metastatic HER2-Positive Breast Carcinoma
Recurrent Breast Adenocarcinoma
Recurrent HER2-Positive Breast Carcinoma
Unresectable Breast Carcinoma

Interventions: Drug: Atezolizumab
Procedure: Biopsy
Procedure: Bone Scan
Procedure: Computed Tomography
Drug: Docetaxel
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Other: Placebo Administration
Biological: Pertuzumab
Other: Quality-of-Life Assessment
Biological: Trastuzumab

First Posted Date: 2017-06-27

Last Posted Date: 2024-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 190

Registration Number: NCT03199885

Locations: 🇺🇸
Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Intermountain Health Lutheran Hospital, Wheat Ridge, Colorado, United States

and more 669 locations

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Phase 1

Terminated

Conditions: Human Papillomavirus
HPV-16
High Grade Squamous Intraepithelial Lesion

Interventions: Drug: Aldesleukin
Biological: E6 T Cell Receptor (TCR)

First Posted Date: 2017-06-23

Last Posted Date: 2021-02-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1

Registration Number: NCT03197025

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Early Phase 1

Completed

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3
Cervical Squamous Cell Carcinoma In Situ
Cervical Squamous Intraepithelial Neoplasia 2
High Grade Cervical Intraepithelial Neoplasia

Interventions: Drug: Imiquimod
Drug: Topical Fluorouracil

First Posted Date: 2017-06-22

Last Posted Date: 2025-04-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT03196180

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Juvenile Myelomonocytic Leukemia
Neurofibromatosis Type 1

Interventions: Procedure: Bone Marrow Aspiration and Biopsy
Drug: Trametinib

First Posted Date: 2017-06-19

Last Posted Date: 2025-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT03190915

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States

and more 54 locations

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Gastric Cancer
Colon Cancer
Rectal Cancer
Gastrointestinal Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Anti-KRAS G12V mTCR PBL
Drug: Aldesleukin

First Posted Date: 2017-06-19

Last Posted Date: 2025-03-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 110

Registration Number: NCT03190941

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Phase 2

Recruiting

Conditions: Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Advanced Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography with Contrast
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Osimertinib

First Posted Date: 2017-06-19

Last Posted Date: 2025-05-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT03191149

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 332 locations

Clonal Evolution in Follicular Lymphoma

Recruiting

Conditions: Follicular Lymphoma

First Posted Date: 2017-06-19

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 200

Registration Number: NCT03190928

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy